CN106821564A - 一种双球囊导管支架 - Google Patents
一种双球囊导管支架 Download PDFInfo
- Publication number
- CN106821564A CN106821564A CN201611245077.0A CN201611245077A CN106821564A CN 106821564 A CN106821564 A CN 106821564A CN 201611245077 A CN201611245077 A CN 201611245077A CN 106821564 A CN106821564 A CN 106821564A
- Authority
- CN
- China
- Prior art keywords
- balloon catheter
- support
- sacculus
- dual balloon
- nylon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000009977 dual effect Effects 0.000 title claims abstract description 28
- 239000000463 material Substances 0.000 claims abstract description 55
- 239000011248 coating agent Substances 0.000 claims abstract description 37
- 238000000576 coating method Methods 0.000 claims abstract description 37
- 210000003708 urethra Anatomy 0.000 claims abstract description 29
- 239000004814 polyurethane Substances 0.000 claims abstract description 10
- 229920002635 polyurethane Polymers 0.000 claims abstract description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000000741 silica gel Substances 0.000 claims abstract description 6
- 229910002027 silica gel Inorganic materials 0.000 claims abstract description 6
- 239000004816 latex Substances 0.000 claims abstract description 4
- 229920000126 latex Polymers 0.000 claims abstract description 4
- 239000004677 Nylon Substances 0.000 claims description 27
- 229920001778 nylon Polymers 0.000 claims description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 claims description 18
- -1 polyoxyethylene Polymers 0.000 claims description 18
- 229910000077 silane Inorganic materials 0.000 claims description 18
- 239000011777 magnesium Substances 0.000 claims description 16
- 229920000139 polyethylene terephthalate Polymers 0.000 claims description 16
- 239000005020 polyethylene terephthalate Substances 0.000 claims description 16
- 229910052749 magnesium Inorganic materials 0.000 claims description 15
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 14
- 239000000956 alloy Substances 0.000 claims description 14
- 229910045601 alloy Inorganic materials 0.000 claims description 12
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 229920002521 macromolecule Polymers 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 235000019441 ethanol Nutrition 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 7
- 229920001577 copolymer Polymers 0.000 claims description 7
- 239000004698 Polyethylene Substances 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 150000004676 glycans Chemical class 0.000 claims description 5
- 229920002674 hyaluronan Polymers 0.000 claims description 5
- 229960003160 hyaluronic acid Drugs 0.000 claims description 5
- 229910052742 iron Inorganic materials 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 229920001282 polysaccharide Polymers 0.000 claims description 5
- 239000005017 polysaccharide Substances 0.000 claims description 5
- 238000003786 synthesis reaction Methods 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 229910000838 Al alloy Inorganic materials 0.000 claims description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 4
- 229910000882 Ca alloy Inorganic materials 0.000 claims description 4
- JHWNWJKBPDFINM-UHFFFAOYSA-N Laurolactam Chemical compound O=C1CCCCCCCCCCCN1 JHWNWJKBPDFINM-UHFFFAOYSA-N 0.000 claims description 4
- 229910019089 Mg-Fe Inorganic materials 0.000 claims description 4
- 229920000299 Nylon 12 Polymers 0.000 claims description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 claims description 4
- 238000004132 cross linking Methods 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 229920000573 polyethylene Polymers 0.000 claims description 4
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 4
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 4
- 239000010935 stainless steel Substances 0.000 claims description 4
- 229910001220 stainless steel Inorganic materials 0.000 claims description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 3
- 102000008186 Collagen Human genes 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 3
- 229920000858 Cyclodextrin Polymers 0.000 claims description 3
- 229920001503 Glucan Polymers 0.000 claims description 3
- 229920002292 Nylon 6 Polymers 0.000 claims description 3
- 229920002302 Nylon 6,6 Polymers 0.000 claims description 3
- ZFXVRMSLJDYJCH-UHFFFAOYSA-N calcium magnesium Chemical compound [Mg].[Ca] ZFXVRMSLJDYJCH-UHFFFAOYSA-N 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 235000010980 cellulose Nutrition 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- 239000002131 composite material Substances 0.000 claims description 3
- 239000002872 contrast media Substances 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 3
- FYIBGDKNYYMMAG-UHFFFAOYSA-N ethane-1,2-diol;terephthalic acid Chemical compound OCCO.OC(=O)C1=CC=C(C(O)=O)C=C1 FYIBGDKNYYMMAG-UHFFFAOYSA-N 0.000 claims description 3
- 239000000835 fiber Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 229920001451 polypropylene glycol Polymers 0.000 claims description 3
- FZHAPNGMFPVSLP-UHFFFAOYSA-N silanamine Chemical compound [SiH3]N FZHAPNGMFPVSLP-UHFFFAOYSA-N 0.000 claims description 3
- 229920002379 silicone rubber Polymers 0.000 claims description 3
- 235000010413 sodium alginate Nutrition 0.000 claims description 3
- 239000000661 sodium alginate Substances 0.000 claims description 3
- 229940005550 sodium alginate Drugs 0.000 claims description 3
- 229920000049 Carbon (fiber) Polymers 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 229920000271 Kevlar® Polymers 0.000 claims description 2
- 229910001069 Ti alloy Inorganic materials 0.000 claims description 2
- MCMNRKCIXSYSNV-UHFFFAOYSA-N ZrO2 Inorganic materials O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 claims description 2
- 125000001931 aliphatic group Chemical group 0.000 claims description 2
- 229910021529 ammonia Inorganic materials 0.000 claims description 2
- 229920005549 butyl rubber Polymers 0.000 claims description 2
- 239000004917 carbon fiber Substances 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 239000004744 fabric Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 238000007654 immersion Methods 0.000 claims description 2
- 239000004761 kevlar Substances 0.000 claims description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims description 2
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 claims description 2
- 238000004806 packaging method and process Methods 0.000 claims description 2
- 238000010422 painting Methods 0.000 claims description 2
- 229920000515 polycarbonate Polymers 0.000 claims description 2
- 239000004417 polycarbonate Substances 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- 150000001336 alkenes Chemical class 0.000 claims 1
- 210000003445 biliary tract Anatomy 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 150000002191 fatty alcohols Chemical class 0.000 claims 1
- 150000002334 glycols Chemical class 0.000 claims 1
- 229920006389 polyphenyl polymer Polymers 0.000 claims 1
- 150000004040 pyrrolidinones Chemical class 0.000 claims 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 1
- 206010013990 dysuria Diseases 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 11
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 230000002485 urinary effect Effects 0.000 description 8
- 210000005077 saccule Anatomy 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 6
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 6
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- MLFHJEHSLIIPHL-UHFFFAOYSA-N isoamyl acetate Chemical compound CC(C)CCOC(C)=O MLFHJEHSLIIPHL-UHFFFAOYSA-N 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 239000011701 zinc Substances 0.000 description 6
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 5
- 239000011572 manganese Substances 0.000 description 5
- 239000007769 metal material Substances 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- 239000004793 Polystyrene Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 206010020718 hyperplasia Diseases 0.000 description 4
- 230000001050 lubricating effect Effects 0.000 description 4
- 229910052748 manganese Inorganic materials 0.000 description 4
- 230000027939 micturition Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 229910000861 Mg alloy Inorganic materials 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000003618 dip coating Methods 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 229940117955 isoamyl acetate Drugs 0.000 description 3
- 238000005461 lubrication Methods 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 239000004800 polyvinyl chloride Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000011669 selenium Substances 0.000 description 3
- 229910052711 selenium Inorganic materials 0.000 description 3
- 210000005070 sphincter Anatomy 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- UBLAMKHIFZBBSS-UHFFFAOYSA-N 3-Methylbutyl pentanoate Chemical compound CCCCC(=O)OCCC(C)C UBLAMKHIFZBBSS-UHFFFAOYSA-N 0.000 description 2
- KBIWNQVZKHSHTI-UHFFFAOYSA-N 4-n,4-n-dimethylbenzene-1,4-diamine;oxalic acid Chemical compound OC(=O)C(O)=O.CN(C)C1=CC=C(N)C=C1 KBIWNQVZKHSHTI-UHFFFAOYSA-N 0.000 description 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 206010063560 Excessive granulation tissue Diseases 0.000 description 2
- 239000001116 FEMA 4028 Substances 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 2
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Natural products OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- 206010046555 Urinary retention Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 2
- 229960004853 betadex Drugs 0.000 description 2
- 230000008468 bone growth Effects 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
- 229910017052 cobalt Inorganic materials 0.000 description 2
- 239000010941 cobalt Substances 0.000 description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 125000000373 fatty alcohol group Chemical group 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 210000001126 granulation tissue Anatomy 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- XQZXYNRDCRIARQ-LURJTMIESA-N iopamidol Chemical compound C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I XQZXYNRDCRIARQ-LURJTMIESA-N 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229910052750 molybdenum Inorganic materials 0.000 description 2
- 239000011733 molybdenum Substances 0.000 description 2
- ALTGURJQVWBILJ-UHFFFAOYSA-N n-(dimethylamino)formamide Chemical compound CN(C)NC=O ALTGURJQVWBILJ-UHFFFAOYSA-N 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 229910052701 rubidium Inorganic materials 0.000 description 2
- IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 229910052712 strontium Inorganic materials 0.000 description 2
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 2
- 239000001384 succinic acid Substances 0.000 description 2
- 229910052718 tin Inorganic materials 0.000 description 2
- BPSIOYPQMFLKFR-UHFFFAOYSA-N trimethoxy-[3-(oxiran-2-ylmethoxy)propyl]silane Chemical compound CO[Si](OC)(OC)CCCOCC1CO1 BPSIOYPQMFLKFR-UHFFFAOYSA-N 0.000 description 2
- 229910052720 vanadium Inorganic materials 0.000 description 2
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000432824 Asparagus densiflorus Species 0.000 description 1
- 206010005042 Bladder fibrosis Diseases 0.000 description 1
- 229910014460 Ca-Fe Inorganic materials 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 229910000881 Cu alloy Inorganic materials 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical class CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 229920000571 Nylon 11 Polymers 0.000 description 1
- 229920003189 Nylon 4,6 Polymers 0.000 description 1
- 229920000572 Nylon 6/12 Polymers 0.000 description 1
- 229920000007 Nylon MXD6 Polymers 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229920000463 Poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- YVPYQUNUQOZFHG-UHFFFAOYSA-N amidotrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229920003233 aromatic nylon Polymers 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- JSLMNNPQKHONFW-UHFFFAOYSA-N benzene naphthalene-1-carboxylic acid Chemical compound C1(=CC=CC2=CC=CC=C12)C(=O)O.C1=CC=CC=C1 JSLMNNPQKHONFW-UHFFFAOYSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000003063 flame retardant Substances 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229960001025 iohexol Drugs 0.000 description 1
- NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 description 1
- 229960004647 iopamidol Drugs 0.000 description 1
- 229960002603 iopromide Drugs 0.000 description 1
- DGAIEPBNLOQYER-UHFFFAOYSA-N iopromide Chemical compound COCC(=O)NC1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I DGAIEPBNLOQYER-UHFFFAOYSA-N 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002717 polyvinylpyridine Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 238000011471 prostatectomy Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 238000010107 reaction injection moulding Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical compound FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008542 thermal sensitivity Effects 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 229920000428 triblock copolymer Polymers 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 235000002374 tyrosine Nutrition 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 201000001988 urethral stricture Diseases 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/95—Instruments specially adapted for placement or removal of stents or stent-grafts
- A61F2/958—Inflatable balloons for placing stents or stent-grafts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/02—Inorganic materials
- A61L31/022—Metals or alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/18—Materials at least partially X-ray or laser opaque
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/02—Methods for coating medical devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/06—Coatings containing a mixture of two or more compounds
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Surgery (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Cardiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Materials For Medical Uses (AREA)
Abstract
本发明公开了一种双球囊导管支架,由定位球囊和柱状球囊组成,其中柱状球囊为双层球囊,其内层球囊选用承压力大于0.5MPa的材料,外层球囊的材料为柔软的聚氨酯、乳胶或硅胶中的一种,柱状球囊的表面装有支架,支架表面涂覆亲水涂层材料。本发明用于腔道放置支架,尤其适用于泌尿外科在尿道内放置支架,作为排尿困难病人临时性支撑,替代导尿管。
Description
技术领域
本发明属于医用生物材料与技术领域,具体涉及双球囊及其支撑的尿道支架。
背景技术
腔道支架根据患者情况不同分为永久性支架和临时性支架,临时性支架在泌尿道中起支撑作用而不是嵌入尿道壁,分为金属支架和可吸收生物降解式支架,是近几年发展起来的临时性支架,它是由高分子的羟基乙酸聚合物(PGA)或乳酸聚合物(PLA)组成。具有组织相容性好、炎症反应小、感染率发生低、表面不存在结晶、无需取出或替换等特点。但是支架放置的方法多采用手术放置,创面大,患者恢复时间较长,本发明采用的双球囊导管,由于前期定位球囊的作用,基本可以实现无创放置,大大降低了患者的手术痛苦,尤其是尿道支架的放置。
尿道支架临床上常用于前列腺增生的患者,大量的临床报告表明支架治疗的近期疗效是确切的,但随着时间的推移其治疗效果有下降的趋势,还有一些问题有待于我们解决:
(1)前列腺增生是一种良性进行性疾病,随年龄的增大而增大,当其继续增大时就有可能超出支架所支撑的范围;
(2)支架植入后架内会有不同程度的肉芽组织和上皮的增生;
(3)如何更好地掌握适应证和禁忌证,选择合适规格的支架并将其放在合适的位置上。
前列腺增生给患者造成的伤害主要是由增生的腺体造成尿道狭窄引发的,增生的腺体促使后尿道狭窄、弯曲变长,使膀胱底部抬高引发尿道梗阻,从而导致患者出现排尿费力,排尿时间延长,残余尿变增多等梗阻症状。而尿道内支架是一种暂时或永久性治疗尿道梗阻的治疗方法,常见的尿道内支架有螺旋支架、聚氨基甲酸乙酯支架、生物可吸收性支架、金属网状支架和热敏性支架等。由于金属支架植入后出现以下5种情况:a.术后血凝块阻塞;b.原有慢性尿潴留的患者,于术前长期带尿管,膀胱逼尿肌纤维化;c.前列腺尿道近端未被支架覆盖;d.架内肉芽组织或上皮过度增生,引起支架狭窄;e.前列腺组织继续增大,超过支架两端,堵塞支架等等生物可吸收性支架:即用加压的聚乳酸制成的可降解的支架,组织反应轻,12-14个月内可被完全吸收,尿道内支架治疗前列腺增生症的近期效果是较好的,但其最终效果如何尚有待观察,但对于不宜行经尿道前列腺切除术的前列腺增生患者不失为一种有效的方法。
高压球囊材料最早应用于高压球囊的材料是聚氯乙烯(PVC)。相对于现今的高压球囊来说,它们相对厚壁与低耐压。在80年代早期,交联乙烯也开始应用。与此同时聚对苯二甲酸乙二醇酯(PET)也应用于高压球囊。这二种材料在相当大的程序上代替了PVC。在80年代晚期,尼龙也开始使用。聚胺脂球囊随后在90年代早期获得应用。尼龙,它的强度不如PET,也不象PE那样有顺应性,但作为一个补偿的是它要比PET软一些,但相对薄壁与强度优点。今天大多数的高压球囊是用PET或尼龙制造的。PET在强度与耐压方向有优势,而尼龙相对软一些。对于支架用的球囊来说,依据球囊的具体尺寸,典型的耐压在2~20个大气压(30至300PSI),球囊的直径越大,其耐压越低。PEF球囊的一个最大优点是PET有一个非同寻常的功能,它可以成型超薄壁厚,与相当精确外形的球囊。因为PET球囊拥有超薄的壁厚,范围从5到50μm,(0.0002英寸至0.002英寸),可以制造超小外形的球囊。高压PET球囊能够生产的直径可以从0.5mm至50mm或更广,可以有多种工作长度,但同时保持非常薄的壁厚。它们可定制成沿着球囊变径,两端锥角可以从1到90度。另外的优点是拥有极佳的热传递特性与透光率。这使得PET球囊适用于ND:YAG激光或其它激光,超声,微波能量应用。
尼龙高压球囊要比PET球囊来得软一些,当然强度也要稍差一些。因此对于指定的爆破压力来说,需要较厚一些的壁厚。这通常意味着PA球囊的外形要比PET球囊要稍大一些,经过体内穿越病变的能力要稍差一些。但正是因为材料较软,它变得更加容易折叠,因此在介入治疗中更加容易从管鞘或导管中收回。
尼龙中的主要品种是尼龙6和尼龙66,占绝对主导地位,其次是尼龙11,尼龙12,尼龙610,尼龙612,另外还有尼龙 1010,尼龙46,尼龙7,尼龙9,尼龙13,新品种有尼龙6I,尼龙9T和特殊尼龙MXD6(阻隔性树脂)等,尼龙的改性品种数量繁多,如增强尼龙,单体浇铸尼龙(MC尼龙),反应注射成型(RIM)尼龙,芳香族尼龙,透明尼龙,高抗冲(超韧)尼龙,电镀尼龙,导电尼龙,阻燃尼龙,尼龙与其他聚合物共混物和合金等,满足不同特殊要求,广泛用作金属,木材等传统材料代用品,作为各种结构材料。
镁是人体代谢必需的元素,在人体内的含量仅次于钾、钠、钙,骨组织中大约占体内所有镁的一半。研究认为镁是许多酶的辅助因子,具有稳定DNA和RNA结构;在体内镁通过肾脏和肠道保持在O.7和1.05mmol/L之间;镁可刺激新骨生长,组织相容性好。镁的主要缺点是低耐蚀性,在pH(7.4-7.6)的生理环境中,镁具有很强的还原作用从而在组织充分愈合前丢失力学完整性,并产生机体无法及时吸收的氢气。早期应用于人体中的镁基材料植入体内后产生大量的气体导致镁无法应用于人体,所以制备可控降解的镁基合金,使镁降解过程中产生的氢气被组织液代谢掉具有非常现实的意义,日前,各种降解及加工性能不同的镁合金材料也成了研究的热点。
增加亲水涂层的涂覆,能增加球囊支架放置过程中的顺应性,为此,在本发明双球囊支架的基础上增加了亲水涂层的研制。
欧洲专利0586324A1 中介绍了一种制备可减少医疗用具表面摩擦的亲水涂层的方法,亲水涂层中除了含有粘合性聚合物、亲水聚合物外,还加入一种无机化合物,如NaCl,目的是提高涂层渗透压,但这种涂层的缺陷在于NaCl 很难溶于有机溶剂中,以悬浮液的形式存在于导管表面,所得的导管看起来比较粗糙,视觉感很差。
美国专利6221425B1 中介绍了一种可用于医疗器械的亲水涂层,需要进行两部反应,首先在导管表面涂一层可聚合的单体溶液,通过一定的反应使其聚合,然后再涂上一层亲水聚合物,干燥处理后得到亲水涂层,这种手段比较容易形成一些不易去除的残留单体,影响导管的安全性。
中国发明专利CN100591389C,是通过在导管的外面直接进行硅胶的涂层,虽然专利中进行了两次的硅胶涂覆,较普通的球囊导管是提高了润滑作用,但是远没有本专利所采用的生物高分子合成高分子通过硅烷偶联剂进行结合的润和性高,同时这些高分子都是可降解的,即使有部分残留也不会对机体造成不必要的二次伤害。
中国发明专利CN1029087123,虽然用到了高分子润滑层,但是高分子所选用的为不同K值的聚乙烯吡咯烷酮,没有通过偶联剂的接合,所形成的膜稳定性比较弱。
中国发明专利CN 102166377 A中所涉及一种医用导管润滑亲水涂层的组合物,该组合物由缩醛类聚合物、亲水聚合物与柠檬酸酸酯增塑剂组成,是通过缩醛反应形成的涂层,容易形成一些小分子,具有潜在的生物危害。
本发明专利所采用的硅烷偶联剂进行生物高分子与合成高分子的接合,从而在粘接界面形成强力较高的化学键,大大改善了粘接强度。增加了涂层(润滑层)的稳定性和持久性。同时生物高分子多糖如透明质酸等具有明确的润滑和防粘连作用。属于环境友好型涂层。特别是一种超润滑的球囊导管系统,能有效降低导管与血管的摩擦系数,有将强的弹性使表面更舒适,更润滑。
经过研究发现,采用本发明设计的双球囊导尿管支撑的可降解的尿道镁合金支架,可以很好的将支架定位在准确的位置上,达到很好的支撑效果,解决了患者排尿困难的问题,又没有影响尿道括约肌的功能,体内动物实验结果表明,由于涂层的超润滑涂层,放置过程不会造成组织尿道粘膜出现肉芽肿等不良反应,最为现实的临床价值在于,由于双球囊的发明和应用,解决了放尿道支架需要住院做手术才能放置的难题,解除了患者的痛苦,具有非常实用的临床应用价值。
发明内容
本发明公开了一种双球囊导管支架,由定位球囊和柱状球囊组成,其中柱状球囊由双层球囊制成,内层球囊材料为承压材料,外层球囊的材料选自聚氨酯、乳胶和硅胶中的一种,所述柱状球囊的表面装有支架。
其中,所述支架的表面涂覆亲水涂层材料,所述涂层材料选自可用于医用导管润滑功能的涂覆高分子材料,具体包含多羟基、羧基和氨基的水溶性高分子材料,比如聚乙烯醇、海藻酸钠、纤维素、葡聚糖、β- 环糊精和由聚乙二醇和聚丙二醇的共聚物、聚乙二醇系列(PEG200、400、600、1000、2000)、PVA系列、聚氧乙烯类物质、聚乙烯吡咯烷酮、壳聚糖、明胶、胶原、胶原质-N- 羟基琥珀酰亚胺以及上述物质的修饰形式以及共聚物透明质酸、脂肪酸(碳链长度2-20,如乙二酸、丙酸、丁二酸)、脂肪醇(碳链长度2-20,如乙二醇、丙二醇、丙三醇、丁二醇)中的一种或两种,其涂覆重量百分比小于10%。
所述内层球囊选用承压力大于0.5MPa的材料,选自芳纶织物增强复合材料、丁基橡胶、硅橡胶、聚氨酯PU、交联聚苯乙烯、聚苯二甲酸乙二醇酯PET、聚四氟乙烯PTFE、聚乙烯PE、尼龙PA、碳纤维、聚碳酸酯PC和聚对苯二甲酸乙二醇酯中的一种或两种以上混合,能承压的内球囊材料优选尼龙及其共聚共混改性材料,具体选自尼龙6、尼龙66、尼龙12 中的一种,优选尼龙12。
本发明所述的双球囊导管支架,柱状球囊表面材料上装有支架,支架选自可降解支架和不可降解支架中的一种。
双球囊导管支架,采用硅烷偶联剂对生物高分子多糖及成膜性好的合成高分子进行交联处理成涂层材料,其制备过程包括以下步骤:
(1)硅烷偶联剂用乙醇稀释成1-25%溶液,雾化或涂覆在固定好支架的双球囊导管支架表面,晾干;
(2)将水性高分子材料溶解在水中,配成0.1-25%溶液备用;
(3)将(1)表面雾化有硅烷偶联剂的双球囊导管支架,放置在(2)种浸泡1分钟-100分钟小时、烘干(温度37-80度);
(4)包装、灭菌。
其中硅烷偶联剂选自由单氨基硅烷、双氨基硅烷和三氨基硅烷其中的一种或组合,硅烷偶联剂的添加量为0.1-5.0%,硅烷偶联剂的溶解介质为乙醇、水、及其它的有机溶剂,反应时间为0-10分钟,获得的润滑涂层:抗张强度为38-45Mpa;延伸率为12-16%;杨氏模量为200-300Mpa;溶胀性为80-100%;接触角为20.49°-26.37°,可以满足在球囊导管上的牢固附着,可以起到增加润滑的作用。
支架材料为不锈钢、钛合金、记忆合金、高纯铁(纯度大于99.0%)、高纯镁(纯度大于99.0%)、镁铁合金(重量百分比为1:0.01-10)、镁锌系合金(重量百分比为1:0.01-1)、镁钙系合金(重量百分比为1:0.01-1)、镁铝系合金(重量百分比为1:0.01-0.1)中的一种或两种组合。
本发明公开的可降解金属材料,添加成分为铁、铜、锌、钴、锰、铬、硒、碘、镍、氟、钼、钒、锡、硅、锶、硼、铷、砷、银、一种或多张元素的组合,元镁合金材料其组分重量百分比为: 铁0-2.0%、铜0-2.0%、锌0-2.0%、钴0-2.0%、锰0-2.0%、铬0-2.0%、硒0-2.0%、碘0-2.0%、镍0-2.0%、氟0-2.0%、钼0-2.0%、钒0-2.0%、锡0-2.0%、硅0-2.0%、锶0-2.0%、硼0-2.0%、铷0-2.0%、银0.1~4%;包括:高纯铁(纯度大于99.0%)、高纯镁(纯度大于99.0%)、镁铁合金(重量百分比为1:0.01-10)、镁锌系合金(重量百分比为1:0.01-1)、镁钙系合金(重量百分比为1:0.01-1)、镁铝系合金(重量百分比为1:0.01-0.1)中的一种或两种组合。其中镁铁合金(重量百分比优选1:0.01-0.1)、镁锌系合金(重量百分比优选1:0.01-0.1),比如:Mg-Nd-Zn-Zr、Mg-Zn-Mn 、Mg-Zn-Mn-Se-Cu 合金,Zn 含量为3.5wt%,Mn 含量为0.5-1.0wt%,Se 含量为0.4-1.0wt%,Cu 含量为0.2-0.5wt%,Mg 余量;镁钙系合金(重量百分比优选1:0.01-0.1),比如:Mg-Zn-Ca-Fe、镁铝系合金(重量百分比优选为1:0.01-0.1,比如:铝(Al):2.0~3.0wt.%、锌(Zn):0.5~1.0wt.%、锰(Mn),Mg 余量:
本发明所述的有机溶剂,选自甲苯、对二甲苯、癸烷、乙酸异戊酯、己烷、苯、二氯甲烷、三氯甲烷、环己酮、甲酮、二甲基甲酰胺、庚烷、二甲氨基甲酰胺、四氢呋喃、石油醚、二甲亚砜、对苯二甲酸乙二醇酯中的一种或两种,优选四氢呋喃、癸烷、乙醇、丙酮、乙酸异戊酯、己烷、二氯甲烷、三氯甲烷、环己酮、二甲基甲酰胺以及庚烷中的一种或两种。
本发明所述的有机溶剂,选自甲苯、对二甲苯、癸烷、乙酸异戊酯、己烷、苯、二氯甲烷、三氯甲烷、环己酮、甲酮、二甲基甲酰胺、庚烷、二甲氨基甲酰胺、四氢呋喃、石油醚、二甲亚砜、对苯二甲酸乙二醇酯中的一种或两种,优选四氢呋喃、三氯甲烷、甲苯、对二甲苯、乙酸异戊酯或己烷中的一种。
本发明所述的双球囊导管支架水溶性涂层:具体包括多糖和蛋白质中的一种,具体选自聚乙烯醇、角叉菜胶、阿拉伯胶、瓜尔胶、纤维蛋白原、淀粉、海藻酸钠、纤维素、聚羟基烷酸酯、果胶酸、actinic acid、经修饰和未修饰纤维蛋白和酪蛋白、羧甲基硫酸酯、白蛋白、硫酸乙酰肝素、肝素、硫酸软骨素、葡聚糖、β- 环糊精和由聚乙二醇和聚丙二醇的共聚物、聚乙二醇系列(PEG200、400、600、1000、2000)、PVA系列、聚氧乙烯类物质、壳聚糖、明胶、胶原、胶原质-N- 羟基琥珀酰亚胺以及上述物质的修饰形式以及共聚物透明质酸、脂肪酸(碳链长度2-20,如乙二酸、丙酸、丁二酸)、脂肪醇(碳链长度2-20,如乙二醇、丙二醇、丙三醇、丁二醇)、氨基酸(20种氨基酸:甘氨酸、丙氨酸、缬氨酸、亮氨酸、异亮氨酸、苯丙氨酸和脯氨酸、色氨酸、丝氨酸、酪氨酸、半胱氨酸、蛋氨酸、天冬酰胺、谷氨酰胺和苏氨酸、天冬氨酸和谷氨酸、赖氨酸、精氨酸和组氨酸)、多肽、聚氨基酸、骨生长因子BMP系列,促进骨生长的营养物质比如市售的骨肽注射液或复方骨肽注射液中的一种、甘露醇、水溶性维生素、脂肪族基于肽的亲水生物材料,聚酯或聚原酸酯基的亲水生物材料,掺入的氨基酸酯,葡萄糖,glyceyl,乳酸盐或咪唑基侧基,乙酸乙烯,丙烯酰胺和甲基丙烯酸酯或任何其衍生物或共聚物,或其共聚物胶束,如三嵌段共聚物PEO-PPO-PEO,PPO-PEO-PPO,聚乙烯基吡啶 - 聚苯乙烯聚乙烯基吡啶(PVP-PS-PVP),PS-PVP-PS,PS-PEO-PS,PEO-PS-PEO。 在某些优选的实施方案中,所述第一组分包含可吸收的材料,是可流动的室温含有可聚合官能团。
本发明所述的双球囊导管支架,包括造影剂,具体选自二氧化锆、硫酸钡和碘制剂中的一种,添加在制备双球囊导管的材料内,也可以添加在涂覆的润滑材料内,添加量重量必为高分子材料的1-20%,优选2-10%,其中球囊所用的材料为加入比如聚氯乙烯、干胶(生胶)、硅橡胶和天然乳胶中加入了显影剂硫酸钡,在制备尿道支架中的覆膜材料中加入常用的造影用碘制剂,比如:泛影葡胺、碘曲伦、泛影酸、碘苯六醇、碘普罗胺及碘必乐(iopamidol)等。
本发明所述的双球囊导管支架,灭菌方式为辐照、电子束及其它灭菌方式,使用过程为该组合物将支架固定在双球囊的柱状球囊上,将支架放入膀胱,通过前置球囊充气定位,然后给柱状球囊充气,撑开支架,将支架放到位后,双球囊泄气,取出导管。
本发明用于尿道的双球囊导管支架设计,如图1所示,通常尿道支架的直径4-7mm,长3-5cm,将支架加工成可以膨胀并具有支撑力的花纹,安装在球囊上的方式可以是通过支架管自身的张力挤压帖服在球囊上,也可以是卷曲黏附在球囊上,随球囊的膨胀撑开而安装到位,安置于前列腺尿道内,使尿道支架的远端各距尿道括约肌3-5mm,使尿道支架既能扩张尿道又不伤及括约肌。
附图说明
图1:双球囊导管支架的结构示意图;
图2:双球囊导管支架中尿道支架撑开时的状态图。
附图标记说明:
1、定位球囊充气导管接头;2、定位球囊充气导管;4、柱状球囊的内层球囊;5、定位球囊;6、柱状球囊充气导管接头;7、柱状球囊充气导管;8、尿道支架;9、柱状球囊的外层球囊。
具体实施方式
实施例一:双球囊支撑的尿道支架
采用硅胶材料制成如图1所示的双球囊导尿管,支架压在或黏附在柱状球囊上,导尿管放入尿道后,通过定位球囊充气导管接头1和定位球囊充气导管2向定位球囊5中打气,定位球囊5定好位,再通过柱状球囊充气导管接头6和柱状球囊充气导管7向柱状球囊的内层球囊4中打气,柱状球囊的外层球囊9将尿道支架8撑开,支撑在尿道部位,两定位球囊5和柱状球囊的内层球囊4放气后撤出,即完成了支架的放置。
制备过程如下:
(1)将金属材料(不锈钢)编制、雕刻、蚀刻或切割成需要的花纹(公开资料可检索),支架直径3mm,长2cm;
(2)将壳聚糖配成2%水溶液;
(3)将(1)中制备的金属支架,通过(2)反复浸涂或均匀喷涂在支架表面,制成涂层复合支架,涂布的材料厚度为0.01-0.05mm。
进行机械性能、溶胀性及接触角的测定,结果如下表:
实施例二:双球囊导尿管覆膜尿道支架
采用乳胶材料制成如图1所示的双球囊导尿管,安装覆膜尿道支架,其制备过程如下:
(1)将可降解金属材料编雕刻、蚀刻或切割成需要的花纹或板条状(公开资料可检索),支架直径3mm,长2cm;
(2)将可降解医用聚氨酯材料溶解于二氯甲烷溶剂中,在四氟乙烯板上铺成0.2-0.3mm厚的薄膜;
(3)将步骤(2)制备的薄膜卷在步骤(1)中制备的金属支架金属材料表面,制成覆膜支架,表面喷涂3%浓度的硅烷偶联剂KH560乙醇溶液;
(4)将步骤(3)中制备的复合材料通过浸涂或喷涂亲水性涂层(1%PVA水溶液),浸泡5分钟,吹干(45-55度)、抛光、打磨制成超润滑覆膜支架。
进行机械性能、溶胀性及接触角的测定,结果如下表:
实施例3:双球囊导尿管混合涂层尿道金属支架
(1)配置2%透明质酸钠(HA)溶液,搅拌12h使其充分溶胀,常温存放备用。将聚乙烯吡咯烷酮(K90-PVP)配置成浓度为6%,在90°热水浴下加热溶胀4小时,将透明质酸与聚乙烯醇按HA:PVP=3:1进行混匀,硅烷偶联剂KH560的加入终浓度为4.0%,搅拌4分钟,减压脱泡,得白色粘稠膜液,将洁净光滑的载玻片与导管同时浸入膜液中,2小时后取出,在烘箱中70℃烘干成膜。
(2)将金属材料(不锈钢)编制、雕刻、蚀刻或切割成需要的花纹(公开资料可检索),支架直径3mm,长2cm;
(3)将步骤(1)中制备的金属支架,通过步骤(2)反复浸涂或均匀喷涂在支架表面,制成涂层复合支架,涂布的材料厚度为0.01-0.05mm。
进行机械性能、溶胀性及接触角的测定,结果如下表:
实施例4:双球囊导尿管尿道支架比格犬植入降解实验观察
将实施例1、2中制备的双球囊导尿管支撑的尿道支架,用辐照消毒。选择6只体重12KG左右的比格犬,分别植入犬的尿道进行观察,每组3只。术后定期观察排尿情况和尿道部位的肿胀程度、血清学、组织切片观察。实验结果表明:实施例1中的支架2周后开始降解,6周降解完全;实施例2中的支架4周开始降解,8周降解完全,尿道部位组织炎症反应轻,组织相容性很好,具有很好的支撑作用。
以上所述,仅是本发明的较佳实施例,并非对本发明做任何形式上的限制,任何未脱离本发明技术方案的内容,依据本发明的技术实质对以上实施例所作的任何简单修改、等同变化与修饰,均属于本发明技术方案的范围。
Claims (10)
1.一种双球囊导管支架,其特征在于,由定位球囊和柱状球囊组成,其中柱状球囊由双层球囊制成,内层球囊的材料为承压材料,外层球囊的材料选自聚氨酯、乳胶和硅胶中的一种,所述柱状球囊的表面装有支架。
2.根据权利要求1所述的双球囊导管支架,其特征在于,所述支架的表面涂覆亲水的涂层材料,所述涂层材料选自可用于医用导管涂覆的高分子材料,具体包含多羟基、羧基和氨基的水溶性高分子材料,所述水溶性高分子材料为聚乙烯醇、海藻酸钠、纤维素、葡聚糖、β-环糊精、聚乙二醇和聚丙二醇的共聚物、聚乙二醇系列、PVA系列、聚氧乙烯类物质、聚乙烯吡咯烷酮、壳聚糖、明胶、胶原、胶原质-N- 羟基琥珀酰亚胺以及上述物质的修饰形式以及共聚物透明质酸、脂肪酸、脂肪醇中的一种或两种以上混合,所述涂层材料的涂覆重量百分比小于10%。
3.根据权利要求1或2所述的双球囊导管支架,其特征在于,所述内层球囊选用承压力大于0.5MPa的材料,选自芳纶织物增强复合材料、丁基橡胶、硅橡胶、聚氨酯PU、交联聚苯乙烯、聚苯二甲酸乙二醇酯PET、聚四氟乙烯PTFE、聚乙烯PE、尼龙PA、碳纤维、聚碳酸酯PC和聚对苯二甲酸乙二醇酯中的一种或两种以上混合。
4.根据权利要求1或2所述的双球囊导管支架,其特征在于,所述内层球囊的材料优选尼龙及其共聚共混改性材料,为尼龙6、尼龙66、尼龙12 中的一种。
5.根据权利要求1或2所述的双球囊导管支架,其特征在于,所述支架选自可降解支架和不可降解支架中的一种。
6.根据权利要求2所述的双球囊导管支架,其特征在于,所述涂层材料采用硅烷偶联剂对生物高分子多糖及成膜性好的合成高分子进行交联处理而成,其制备过程包括以下步骤:
(1)硅烷偶联剂用乙醇稀释成1-25%溶液,雾化或涂覆在固定好支架的双球囊导管支架表面,晾干;
(2)将水性高分子材料溶解在水中,配成0.1-25%溶液备用;
(3)将步骤(1)中表面雾化有硅烷偶联剂的双球囊导管支架,放置在步骤(2)配成的溶液中浸泡1-100分钟、温度37-80度下烘干;
(4)包装、灭菌。
7.根据权利要求2所述的双球囊导管支架,其特征在于,所述涂层材料采用硅烷偶联剂对生物高分子多糖及成膜性好的合成高分子进行交联处理而成,所述硅烷偶联剂选自由单氨基硅烷、双氨基硅烷和三氨基硅烷其中的一种或两种以上组合,所述硅烷偶联剂的添加量为0.1-5.0%,所述硅烷偶联剂的溶解介质为乙醇、水、及其它的有机溶剂,反应时间为0-10分钟,所述涂层材料的抗张强度为38-45Mpa,延伸率为12-16%,杨氏模量为200-300Mpa,溶胀性为80-100%,接触角为20.49°-26.37°。
8.根据权利要求1或2所述的双球囊导管支架,其特征在于,所述支架的材料为不锈钢、钛合金、记忆合金、高纯铁、高纯镁、镁铁合金、镁锌系合金、镁钙系合金、镁铝系合金中的一种或两种以上组合。
9.根据权利要求1或6所述的双球囊导管支架,其特征在于,还包括添加于其制备材料内的造影剂,为二氧化锆、硫酸钡和碘制剂中的一种,所述造影剂的灭菌方式为辐照或电子束。
10.根据权利要求1、2、6或7所述的双球囊导管支架,其特征在于,可用于腔道支架的放置,适用于食道、肠道、胆道以及尿道,尤其适用于尿道支架的放置,用以替代手术放置,减少患者痛苦。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611245077.0A CN106821564A (zh) | 2016-12-29 | 2016-12-29 | 一种双球囊导管支架 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611245077.0A CN106821564A (zh) | 2016-12-29 | 2016-12-29 | 一种双球囊导管支架 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106821564A true CN106821564A (zh) | 2017-06-13 |
Family
ID=59114085
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611245077.0A Pending CN106821564A (zh) | 2016-12-29 | 2016-12-29 | 一种双球囊导管支架 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106821564A (zh) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108742959A (zh) * | 2018-04-21 | 2018-11-06 | 李皇德 | 一种血管球囊,球囊支架药物释放装置及其药物释放方法 |
CN108926738A (zh) * | 2018-07-06 | 2018-12-04 | 苏州盖德精细材料有限公司 | 一种高效抗菌的硅橡胶医用敷料的制备方法 |
CN109010929A (zh) * | 2018-09-23 | 2018-12-18 | 湖南博隽生物医药有限公司 | 一种医用导尿管 |
CN109096724A (zh) * | 2018-06-22 | 2018-12-28 | 宁波帅特龙集团有限公司 | 一种内开手柄 |
CN109481740A (zh) * | 2019-01-11 | 2019-03-19 | 杭州劲驰医疗器械有限公司 | 一种仿生高分子材料的制备及应用 |
CN109908409A (zh) * | 2019-04-10 | 2019-06-21 | 深圳市美好创亿医疗科技有限公司 | 硅酮支架制备方法及硅酮支架 |
CN111035813A (zh) * | 2018-10-15 | 2020-04-21 | 复旦大学附属中山医院 | 一种液体创可贴式冠脉带膜支架及其制作方法 |
CN111839849A (zh) * | 2020-07-17 | 2020-10-30 | 易浦润(上海)生物技术有限公司 | 一种尿道支架及其制备方法和应用 |
EP3791831A1 (de) * | 2019-09-10 | 2021-03-17 | AIT Austrian Institute of Technology GmbH | Implantat zur behandlung einer bandscheibe |
CN114349996A (zh) * | 2021-12-03 | 2022-04-15 | 广东省科学院健康医学研究所 | 超滑材料及其制备方法和应用 |
CN115227470A (zh) * | 2022-07-05 | 2022-10-25 | 上海英威思医疗科技有限公司 | 一种球囊导管 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030153899A1 (en) * | 1998-02-04 | 2003-08-14 | Uzi Eshel | Urethral catheter and guide |
CN101822866A (zh) * | 2009-03-02 | 2010-09-08 | 东莞市迪凯精密管材有限公司 | 双球囊血管扩张导管 |
CN104189963A (zh) * | 2014-05-13 | 2014-12-10 | 奚廷斐 | 降低可全降解镁合金血管支架降解速率的表面涂层制备方法 |
CN205569125U (zh) * | 2015-09-30 | 2016-09-14 | 苏州纳晶医药技术有限公司 | 一种双球囊导尿管支撑的可降解的尿道支架组合物 |
CN106178231A (zh) * | 2016-08-03 | 2016-12-07 | 武汉福脉医疗科技有限公司 | 医用双层耐高压球囊及其制备方法 |
-
2016
- 2016-12-29 CN CN201611245077.0A patent/CN106821564A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030153899A1 (en) * | 1998-02-04 | 2003-08-14 | Uzi Eshel | Urethral catheter and guide |
CN101822866A (zh) * | 2009-03-02 | 2010-09-08 | 东莞市迪凯精密管材有限公司 | 双球囊血管扩张导管 |
CN104189963A (zh) * | 2014-05-13 | 2014-12-10 | 奚廷斐 | 降低可全降解镁合金血管支架降解速率的表面涂层制备方法 |
CN205569125U (zh) * | 2015-09-30 | 2016-09-14 | 苏州纳晶医药技术有限公司 | 一种双球囊导尿管支撑的可降解的尿道支架组合物 |
CN106178231A (zh) * | 2016-08-03 | 2016-12-07 | 武汉福脉医疗科技有限公司 | 医用双层耐高压球囊及其制备方法 |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108742959A (zh) * | 2018-04-21 | 2018-11-06 | 李皇德 | 一种血管球囊,球囊支架药物释放装置及其药物释放方法 |
CN109096724A (zh) * | 2018-06-22 | 2018-12-28 | 宁波帅特龙集团有限公司 | 一种内开手柄 |
CN108926738A (zh) * | 2018-07-06 | 2018-12-04 | 苏州盖德精细材料有限公司 | 一种高效抗菌的硅橡胶医用敷料的制备方法 |
CN109010929B (zh) * | 2018-09-23 | 2021-08-13 | 湖南博隽生物医药有限公司 | 一种医用导尿管 |
CN109010929A (zh) * | 2018-09-23 | 2018-12-18 | 湖南博隽生物医药有限公司 | 一种医用导尿管 |
CN111035813A (zh) * | 2018-10-15 | 2020-04-21 | 复旦大学附属中山医院 | 一种液体创可贴式冠脉带膜支架及其制作方法 |
CN111035813B (zh) * | 2018-10-15 | 2022-02-18 | 复旦大学附属中山医院 | 一种液体创可贴式冠脉带膜支架及其制作方法 |
CN109481740A (zh) * | 2019-01-11 | 2019-03-19 | 杭州劲驰医疗器械有限公司 | 一种仿生高分子材料的制备及应用 |
CN109481740B (zh) * | 2019-01-11 | 2022-09-20 | 杭州劲驰医疗器械有限公司 | 一种仿生高分子材料的制备及应用 |
CN109908409A (zh) * | 2019-04-10 | 2019-06-21 | 深圳市美好创亿医疗科技有限公司 | 硅酮支架制备方法及硅酮支架 |
EP3791831A1 (de) * | 2019-09-10 | 2021-03-17 | AIT Austrian Institute of Technology GmbH | Implantat zur behandlung einer bandscheibe |
CN111839849A (zh) * | 2020-07-17 | 2020-10-30 | 易浦润(上海)生物技术有限公司 | 一种尿道支架及其制备方法和应用 |
CN114349996A (zh) * | 2021-12-03 | 2022-04-15 | 广东省科学院健康医学研究所 | 超滑材料及其制备方法和应用 |
CN115227470A (zh) * | 2022-07-05 | 2022-10-25 | 上海英威思医疗科技有限公司 | 一种球囊导管 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106821564A (zh) | 一种双球囊导管支架 | |
Zhou et al. | 4D printing of shape memory vascular stent based on βCD‐g‐Polycaprolactone | |
EP0565604B1 (en) | Catheter for drug delivery system | |
Beiko et al. | Urinary tract biomaterials | |
US20050049691A1 (en) | Polymeric reconstrainable, repositionable, detachable, percutaneous endovascular stentgraft | |
CN101172168B (zh) | 胺糖聚糖负载cd133抗体的金属血管支架涂层与制法 | |
JP6949819B2 (ja) | 形状記憶型外ステントの開発及び血管適用 | |
JP2009525809A (ja) | 表面浸食性ポリエステルによる薬剤送達コーティングを備える埋め込み式医療デバイス | |
BE1006819A7 (nl) | Polyurethaan gecoate prothesen (stents) voor de behandeling van bloedvatvernauwingen. | |
EP3193954B1 (en) | Medical balloon coated with therapeutic agent, carboxylic acid, and salt thereof | |
WO2017054433A1 (zh) | 弹性模量可调的聚氨酯组合物、支架复合物及其制备方法 | |
JP2004534579A (ja) | 多糖類生体材料及びその使用 | |
WO1999038546A1 (en) | Hydrophilic coating for an intracorporeal medical device | |
WO2007113833A2 (en) | Minimally invasive system for treating hollow organ dilatation | |
CN111803718B (zh) | 一种抗纤维化药物缓释涂层及其制备方法 | |
CN100409904C (zh) | 可生物降解的镁合金血管支架 | |
Levy et al. | Biodegradable inflatable balloon for reducing radiation adverse effects in prostate cancer | |
JP2005530561A (ja) | 薬剤送達用シリコーン混合物及び複合体 | |
WO2011130539A2 (en) | Liquid cast biodegradable arterial stent | |
CN102488932A (zh) | 涂覆酰化壳聚糖与聚酯类共混物药物涂层的镁合金支架 | |
CN101279112A (zh) | 一种表面涂覆有plga共混物药物洗脱性涂层的血管支架 | |
US20080132991A1 (en) | Method for Ionically Cross-Linking Gellan Gum for Thin Film Applications and Medical Devices Produced Therefrom | |
CN201734994U (zh) | 一种以梯度浓度方式负载药物的载药冠脉支架 | |
CN114652902A (zh) | 一种x射线下可视化的3d打印血管内可吸收支架及其制备方法 | |
Nazeer et al. | Polymers in medicine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170613 |